{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T13:17:16Z","timestamp":1778246236184,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.transproceed.2025.03.029","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T17:41:46Z","timestamp":1746726106000},"page":"784-792","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preemptive Conversion to mTOR Inhibition to Prevent Primary Cytomegalovirus Infection in Kidney Transplantation with High-Risk Serostatus"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7884-9285","authenticated-orcid":false,"given":"Jan","family":"Paulwitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Vonbrunn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Heller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Dieterle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendrik","family":"Apel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Schiffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Wiesener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Dienemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.transproceed.2025.03.029_bib0001","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJM199912023412303","article-title":"Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant","volume":"341","author":"Wolfe","year":"1999","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.transproceed.2025.03.029_bib0002","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1056\/NEJM198502283120905","article-title":"The quality of life of patients with end-stage renal disease","volume":"312","author":"Evans","year":"1985","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"10.1016\/j.transproceed.2025.03.029_bib0003","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ajt.12006","article-title":"CMV: Prevention, Diagnosis and Therapy","volume":"13","author":"Kotton","year":"2013","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.transproceed.2025.03.029_bib0004","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.transproceed.2025.03.029_bib0005","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1523-1755.2004.00735.x","article-title":"Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival","volume":"66","author":"Sagedal","year":"2004","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.transproceed.2025.03.029_bib0006","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14583","article-title":"Outcomes among CMV-mismatched and highly sensitized kidney transplant recipients who develop neutropenia","volume":"36","author":"Brar","year":"2022","journal-title":"Clin Transplant"},{"issue":"25","key":"10.1016\/j.transproceed.2025.03.029_bib0007","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1056\/NEJMra064928","article-title":"Infection in solid-organ transplant recipients","volume":"357","author":"Fishman","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.transproceed.2025.03.029_bib0008","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/ajt.15183","article-title":"Cytomegalovirus mismatch still negatively affects patient and graft survival in the era of routine prophylactic and preemptive therapy: A paired kidney analysis","volume":"19","author":"Leeaphorn","year":"2019","journal-title":"Am J Transplant"},{"issue":"Suppl 3","key":"10.1016\/j.transproceed.2025.03.029_bib0009","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.transproceed.2025.03.029_bib0010","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/ajt.16132","article-title":"CMV high-risk status and posttransplant outcomes in kidney transplant recipients treated with belatacept","volume":"21","author":"Karadkhele","year":"2021","journal-title":"Am J Transplant"},{"issue":"11","key":"10.1016\/j.transproceed.2025.03.029_bib0011","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1097\/01.TP.0000164512.99703.AD","article-title":"Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients","volume":"79","author":"Wiltshire","year":"2005","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.transproceed.2025.03.029_bib0012","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00043-19","article-title":"Progress and challenges in the prevention, diagnosis, and management of cytomegalovirus infection in transplantation","volume":"34","author":"Limaye","year":"2020","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"10.1016\/j.transproceed.2025.03.029_bib0013","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/cid\/ciaa1713","article-title":"Letermovir and Maribavir for the Treatment and Prevention of Cytomegalovirus Infection in Solid Organ and Stem Cell Transplant Recipients","volume":"73","author":"Imlay","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.transproceed.2025.03.029_bib0014","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cmi.2022.07.001","article-title":"Cytomegalovirus infection in transplant recipients: newly approved additions to our armamentarium","volume":"29","author":"Khawaja","year":"2023","journal-title":"Clin Microbiol Infect"},{"issue":"25","key":"10.1016\/j.transproceed.2025.03.029_bib0015","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.transproceed.2025.03.029_bib0016","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/j.1600-6143.2012.04002.x","article-title":"CMV late phase-induced mTOR activation is essential for efficient virus replication in polarized human macrophages","volume":"12","author":"Poglitsch","year":"2012","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.transproceed.2025.03.029_bib0017","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1681\/ASN.2020121753","article-title":"mTOR Inhibitors Prevent CMV Infection through the Restoration of Functional \u03b1\u03b2 and \u03b3\u03b4 T cells in Kidney Transplantation","volume":"33","author":"Kaminski","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.transproceed.2025.03.029_bib0018","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/01.tp.0000219703.39149.85","article-title":"Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials","volume":"81","author":"Webster","year":"2006","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.transproceed.2025.03.029_bib0019","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2019.01.041","article-title":"An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients","volume":"96","author":"Sommerer","year":"2019","journal-title":"Kidney Int"},{"issue":"11","key":"10.1016\/j.transproceed.2025.03.029_bib0020","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/ajt.15480","article-title":"Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study","volume":"19","author":"Berger","year":"2019","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.transproceed.2025.03.029_bib0021","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1111\/ajt.13327","article-title":"Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses","volume":"15","author":"Tedesco-Silva","year":"2015","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.transproceed.2025.03.029_bib0022","first-page":"1835","article-title":"Conversion to mTOR Inhibitor to Reduce the Incidence of Cytomegalovirus Recurrence in Kidney Transplant Recipients Receiving Preemptive Treatment: A Prospective","volume":"107","author":"Viana","year":"2023","journal-title":"Randomized Trial. Transplantation"},{"issue":"5","key":"10.1016\/j.transproceed.2025.03.029_bib0023","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13713","article-title":"Comparison of standard versus low-dose valganciclovir regimens for cytomegalovirus prophylaxis in high-risk liver transplant recipients","volume":"23","author":"Bixby","year":"2021","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"10.1016\/j.transproceed.2025.03.029_bib0024","doi-asserted-by":"crossref","DOI":"10.1111\/petr.13650","article-title":"Burden of cytomegalovirus DNAemia among pediatric renal transplant patients on antiviral prophylaxis: A hospital-based analysis","volume":"24","author":"Mehta","year":"2020","journal-title":"Pediatr Transplant"},{"issue":"1","key":"10.1016\/j.transproceed.2025.03.029_bib0025","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14233","article-title":"Five-year single-center analysis of cytomegalovirus viremia in kidney transplant recipients and possible implication for novel prophylactic therapy approaches","volume":"26","author":"Trappe","year":"2024","journal-title":"Transpl Infect Dis"},{"issue":"2","key":"10.1016\/j.transproceed.2025.03.029_bib0026","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/tid.12349","article-title":"Increased risk of breakthrough infection among cytomegalovirus donor-positive\/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis","volume":"17","author":"Stevens","year":"2015","journal-title":"Transpl Infect Dis"},{"issue":"2","key":"10.1016\/j.transproceed.2025.03.029_bib0027","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00007890-200101270-00019","article-title":"A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus\/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts","volume":"71","author":"MacDonald","year":"2001","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.transproceed.2025.03.029_bib0028","first-page":"S361","article-title":"for the US and Global Multicenter Sirolimus Trials Groups. Two-year follow-up of the pivotal multicenter trials of sirolimus.: Abstract# 960","volume":"69","author":"Kahan","year":"2000","journal-title":"Transplantation"},{"issue":"12","key":"10.1016\/j.transproceed.2025.03.029_bib0029","article-title":"Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients","volume":"12","author":"Hahn","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.transproceed.2025.03.029_bib0030","doi-asserted-by":"crossref","DOI":"10.1111\/petr.14493","article-title":"Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight-based dosed valganciclovir prophylaxis","volume":"27","author":"Liverman","year":"2023","journal-title":"Pediatr Transplant"},{"issue":"4","key":"10.1016\/j.transproceed.2025.03.029_bib0031","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41409-023-01920-w","article-title":"Cytomegalovirus breakthrough and resistance during letermovir prophylaxis","volume":"58","author":"Perchetti","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.transproceed.2025.03.029_bib0032","doi-asserted-by":"crossref","DOI":"10.3390\/v15091884","article-title":"Cytomegalovirus Infection after Allogeneic Hematopoietic Cell Transplantation under 100-Day Letermovir Prophylaxis: A Real-World 1-Year Follow-Up Study","volume":"15","author":"Nho","year":"2023","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/j.transproceed.2025.03.029_bib0033","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.healun.2021.12.005","article-title":"Cytomegalovirus prevention in thoracic organ transplantation: A single-center evaluation of letermovir prophylaxis","volume":"41","author":"Saullo","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.transproceed.2025.03.029_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105565","article-title":"Delayed graft function and rejection are risk factors for cytomegalovirus breakthrough infection in kidney transplant recipients","volume":"167","author":"Kleinherenbrink","year":"2021","journal-title":"Pharmacol Res"},{"issue":"4","key":"10.1016\/j.transproceed.2025.03.029_bib0035","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13570","article-title":"Letermovir prophylaxis in solid organ transplant-Assessing CMV breakthrough and tacrolimus drug interaction","volume":"23","author":"Winstead","year":"2021","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"10.1016\/j.transproceed.2025.03.029_bib0036","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/ajt.13978","article-title":"Cancer Screening Recommendations for Solid Organ Transplant Recipients: A Systematic Review of Clinical Practice Guidelines","volume":"17","author":"Acuna","year":"2017","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.transproceed.2025.03.029_bib0037","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194975","article-title":"Effects of mTOR-Is on malignancy and survival following renal transplantation: A systematic review and meta-analysis of randomized trials with a minimum follow-up of 24 months","volume":"13","author":"Wolf","year":"2018","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.transproceed.2025.03.029_bib0038","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1111\/ajt.14948","article-title":"De novo or early conversion to everolimus and long-term cancer outcomes in kidney transplant recipients: A trial-based linkage study","volume":"18","author":"Ying","year":"2018","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.transproceed.2025.03.029_bib0039","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/jama.2023.9106","article-title":"Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial","volume":"330","author":"Limaye","year":"2023","journal-title":"JAMA"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134525002246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134525002246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T12:37:44Z","timestamp":1778243864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134525002246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0041134525002246"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2025.03.029","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preemptive Conversion to mTOR Inhibition to Prevent Primary Cytomegalovirus Infection in Kidney Transplantation with High-Risk Serostatus","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2025.03.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}